Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04190979
Other study ID # VP-000 214
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date March 17, 2018
Est. completion date February 25, 2019

Study information

Verified date December 2019
Source Medyria AG
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Pre-market, single-arm, prospective, open-label, multi-center clinical trial aimed at assessing the safety and the performance of the Medyria TrackCath system in patients undergoing endovascular intervention.


Description:

Pre-market, single-arm, prospective, open-label, multi-center clinical trial aimed at assessing the safety and the performance of the Medyria TrackCath system in patients above the age of 18 years who have been diagnosed with aneurysms in the thoracoabdominal (TAAA) or abdominal (AAA) aorta and require endovascular intervention.

The TrackCath System is a non-implantable disposable device, intended to measure real-time changes in the Blood Flow Velocity and to provide a pathway for delivering third-party guidewires and/or catheters.

Following patient consent, data is collected until discharge.

To reach 80% power, a total number of 32 patients (minimum 42 target orifices) is scheduled, including a minimum of 8 roll-in patients for the training phase, which comprises at least two successful cases per center.


Recruitment information / eligibility

Status Completed
Enrollment 40
Est. completion date February 25, 2019
Est. primary completion date February 25, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patient has signed and understood the approved Informed Consent form and is able to meet the proposed study proceedings (CIP).

- Patient is =18 years of age

- Need for standard or complex EVAR of AAA according to the relevant guidelines:

- Asymptomatic aneurysms with a diameter > 55mm in men and > 50 mm in woman

- Aneurysm-growth exceeds 10mm/year

- Patient requires at least one cannulation during which requires at least one cannulation (e.g. fenestration of endograft, side-branch and/or contralateral leg of endograft)

Exclusion Criteria:

- Patient is generally contraindicated for EVAR

- Patient requires an emergency surgery

- Patient with an increased risk of aneurysm rupture or saccular aneurysm, aneurysm with isolated wall protuberances or penetrating aortic ulcer

- Patient with a dissecting acutely ruptured or leaking aneurysm or an acute vascular injury caused by a trauma

- Patient with stroke or transient ischemic attack (TIA) within the last 6 months prior to baseline

- Patient with myocardial infarction (MI) with the last 3 months prior to baseline

- Patient with acute or chronic renal failure (including dialysis); Creatinine > 2.00 mg/dl or > 182 µmol/L

- Patient with co-morbidities that constitutes an unacceptable risk (for example chronic obstructive pulmonary disease (COPD), liver failure, immunosuppression, polyneuropathy and hematological diseases)

- Patient with bleeding history or coagulopathy

- Patient with contraindication or allergies to take anticoagulants, antiplatelet drugs or contrast media

- Life expectancy of less than 5 years

- Female patient that is pregnant, is planning on becoming pregnant in the next month or is breastfeeding

- Patient with inability to obtain vascular access

- Patient has an active local or systemic infection

- Patient is currently participating in another investigational study where the endpoints have not yet been achieved

- Patient has a mental illness, and/or been diagnosed as clinically depressed or belongs to a vulnerable population (e.g., prisoner, severe drug abuser, developmentally disabled) that would compromise the ability to provide informed consent.

- Patient has an obstructed or inadequate vasculature by means of tortuous anatomy hindering the TC catheter to reach target orifice(s)

- Patient has an elevated risk of plaque dislodgment.

Study Design


Intervention

Device:
Medyria TrackCath System
The TrackCath System is a non-implantable device and consists of the TrackCath Catheter and the TrackCath Equipment. It is designed to support the successful positioning of third-party guidewires and catheters in the arterial vasculature to detect and cannulate side branches during endovascular aneurysm repair procedures through the measurement of real-time blood flow velocity changes.

Locations

Country Name City State
Germany Universitätsklinikum RWTH Aachen Aachen
Germany Heinrich-Heine University Düsseldorf Düsseldorf
Germany Universitäres Herzzentrum Hamburg Hamburg
Germany Universitätklinikum Leipzig Leipzig

Sponsors (5)

Lead Sponsor Collaborator
Medyria AG Axxos GmbH, Medical Mind RCS GmbH, StatConsult Gesellschaft für klinische und Versorgungsforschung mbH, Worldwide Clinical Trials

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Procedural Success Rate Successful TrackCath delivery of the distal end of the guidewire or of the 4 French catheter to the selected targeted orifice(s). Intra-operative
Primary Primary Safety (All SADEs) Occurrence of Serious Adverse Device Effects (SADE) Up to discharge (expected to be within 1 month)
Secondary Secondary Safety (All AEs) All Adverse Events Up to discharge (expected to be within 1 month)
Secondary Procedural Parameters (contrast dye) Amount of contrast dye used (ml) Intra-operative
Secondary Procedural Parameters (procedural times) Exposure time to X-ray (min); total duration of the procedure (min); duration of the target orifice identification and cannulation (min). Intra-operative
Secondary Procedural Parameters (Blood flow velocity) Blood flow velocity changes between above orifice and at orifice (m/s). Intra-operative
Secondary Surgeon satisfaction rate Surgeon satisfaction on the use of the TrackCath catheter and the Blood Flow Velocity sensor, expressed on a scale from 1 (very bad) to 5 (very good). Intra-operative
See also
  Status Clinical Trial Phase
Recruiting NCT05538351 - A Study to Support the Development of the Enhanced Fluid Assessment Tool for Patients With Acute Kidney Injury
Recruiting NCT06027788 - CTSN Embolic Protection Trial N/A
Completed NCT03938038 - Guidance of Ultrasound in Intensive Care to Direct Euvolemia N/A
Recruiting NCT05805709 - A Patient-centered Trial of a Process-of-care Intervention in Hospitalized AKI Patients: the COPE-AKI Trial N/A
Recruiting NCT05318196 - Molecular Prediction of Development, Progression or Complications of Kidney, Immune or Transplantation-related Diseases
Recruiting NCT05897840 - Continuous Central Venous Oxygen Saturation Measurement as a Tool to Predict Hemodynamic Instability Related to Renal Replacement Therapy in Critically Ill Patients N/A
Recruiting NCT04986137 - Fractional Excretion of Urea for the Differential Diagnosis of Acute Kidney Injury in Cirrhosis
Terminated NCT04293744 - Acute Kidney Injury After Cardiac Surgery N/A
Completed NCT04095143 - Ultrasound Markers of Organ Congestion in Severe Acute Kidney Injury
Not yet recruiting NCT06026592 - Detection of Plasma DNA of Renal Origin in Kidney Transplant Patients
Not yet recruiting NCT06064305 - Transcriptional and Proteomic Analysis of Acute Kidney Injury
Terminated NCT03438877 - Intensive Versus Regular Dosage For PD In AKI. N/A
Terminated NCT03305549 - Recovery After Dialysis-Requiring Acute Kidney Injury N/A
Completed NCT05990660 - Renal Assist Device (RAD) for Patients With Renal Insufficiency Undergoing Cardiac Surgery N/A
Completed NCT04062994 - A Clinical Decision Support Trial to Reduce Intraoperative Hypotension
Terminated NCT02860130 - Clinical Evaluation of Use of Prismocitrate 18 in Patients Undergoing Acute Continuous Renal Replacement Therapy (CRRT) Phase 3
Completed NCT06000098 - Consol Time and Acute Kidney Injury in Robotic-assisted Prostatectomy
Not yet recruiting NCT05548725 - Relation Between Acute Kidney Injury and Mineral Bone Disease
Completed NCT02665377 - Prevention of Akute Kidney Injury, Hearttransplant, ANP Phase 3
Terminated NCT03539861 - Immunomodulatory Biomimetic Device to Treat Myocardial Stunning in End-stage Renal Disease Patients N/A